Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Becker, MatthiasStrengert, Monika
Junker, Daniel
Kaiser, Philipp D
Kerrinnes, Tobias
Traenkle, Bjoern
Dinter, Heiko
Häring, Julia
Ghozzi, Stéphane
Zeck, Anne
Weise, Frank
Peter, Andreas
Hörber, Sebastian
Fink, Simon
Ruoff, Felix
Dulovic, Alex
Bakchoul, Tamam
Baillot, Armin
Lohse, Stefan
Cornberg, Markus
Illig, Thomas
Gottlieb, Jens
Smola, Sigrun
Karch, André
Berger, Klaus
Rammensee, Hans-Georg
Schenke-Layland, Katja
Nelde, Annika
Märklin, Melanie
Heitmann, Jonas S
Walz, Juliane S
Templin, Markus
Joos, Thomas O
Rothbauer, Ulrich
Krause, Gérard
Schneiderhan-Marra, Nicole
Issue Date
2021-02-19
Metadata
Show full item recordAbstract
The humoral immune response to SARS-CoV-2 is a benchmark for immunity and detailed analysis is required to understand the manifestation and progression of COVID-19, monitor seroconversion within the general population, and support vaccine development. The majority of currently available commercial serological assays only quantify the SARS-CoV-2 antibody response against individual antigens, limiting our understanding of the immune response. To overcome this, we have developed a multiplex immunoassay (MultiCoV-Ab) including spike and nucleocapsid proteins of SARS-CoV-2 and the endemic human coronaviruses. Compared to three broadly used commercial in vitro diagnostic tests, our MultiCoV-Ab achieves a higher sensitivity and specificity when analyzing a well-characterized sample set of SARS-CoV-2 infected and uninfected individuals. We find a high response against endemic coronaviruses in our sample set, but no consistent cross-reactive IgG response patterns against SARS-CoV-2. Here we show a robust, high-content-enabled, antigen-saving multiplex assay suited to both monitoring vaccination studies and facilitating epidemiologic screenings for humoral immunity towards pandemic and endemic coronaviruses.Citation
Nat Commun. 2021 Mar 11;12(1):1577. doi: 10.1038/s41467-021-21609-2.Affiliation
HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.Publisher
NPGJournal
Nature communicationsPubMed ID
33608538Type
ArticleLanguage
enEISSN
2041-1723ae974a485f413a2113503eed53cd6c53
10.1038/s41467-021-20973-3
Scopus Count
The following license files are associated with this item:
- Creative Commons
Related articles
- Comparison of 2 fully automated tests detecting antibodies against nucleocapsid N and spike S1/S2 proteins in COVID-19.
- Authors: Flinck H, Rauhio A, Luukinen B, Lehtimäki T, Haapala AM, Seiskari T, Aittoniemi J
- Issue date: 2021 Jan
- A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 Infection and Its Application in a Population-Based Survey by Mail.
- Authors: Egorov AI, Griffin SM, Fuzawa M, Kobylanski J, Grindstaff R, Padgett W, Simmons S, Hallinger DR, Styles JN, Wickersham L, Sams E, Hudgens E, Wade TJ
- Issue date: 2021 Oct 31
- A 10-Minute "Mix and Read" Antibody Assay for SARS-CoV-2.
- Authors: Rusanen J, Kareinen L, Levanov L, Mero S, Pakkanen SH, Kantele A, Amanat F, Krammer F, Hedman K, Vapalahti O, Hepojoki J
- Issue date: 2021 Jan 20
- A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
- Authors: Solastie A, Virta C, Haveri A, Ekström N, Kantele A, Miettinen S, Lempainen J, Jalkanen P, Kakkola L, Dub T, Julkunen I, Melin M
- Issue date: 2021 Dec 22
- Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
- Authors: Yokoyama R, Kurano M, Morita Y, Shimura T, Nakano Y, Qian C, Xia F, He F, Kishi Y, Okada J, Yoshikawa N, Nagura Y, Okazaki H, Moriya K, Seto Y, Kodama T, Yatomi Y
- Issue date: 2021